Glucagon-like peptide 1

Base Information

• Chemical Name: Glucagon-like peptide 1
• CAS No.: 89750-14-1
• Molecular Formula: C149H226N40O45
• Molecular Weight: 3297.62974
• ChEMBL ID: CHEMBL410972
• DSSTox Substance ID: DTXSID701343589
• Mol file: 89750-14-1.mol

Synonyms:GLP 1;GLP-1;Glucagon Like Peptide 1;Glucagon-Like Peptide 1;Glucagon-Like Peptide-1

Chemical Property of Glucagon-like peptide 1

Chemical Property:

• XLogP3: -14.2
• Hydrogen Bond Donor Count: 49
• Hydrogen Bond Acceptor Count: 50
• Rotatable Bond Count: 109
• Exact Mass: 3296.6659301
• Heavy Atom Count: 234
• Complexity: 7660

Purity/Quality:

99% ^*data from raw suppliers

Glucagon-like Peptide 1 ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

Useful:

• Canonical SMILES: CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N
• Isomeric SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N
• Recent ClinicalTrials: Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments
• Recent EU Clinical Trials: A phase II study to investigate the protective effects of Glucagon--like Peptide--1 (GLP--1) in patients undergoing elective angioplasty and stenting.
• Description: GLP-1 stimulates pancreatic β cells to secrete insulin as an incretin hormone. GLP-1 also has additional actions, including suppression of glucagon secretion, inhibition of gastric motility, and promotion of satiety. GLP-1 was first identified in the early 1980s, following the cloning of the proglucagon gene. The biological activity of GLP-1 was investigated initially by using the N-terminal extended forms of GLP-1(1–37 and 1–36 amide). However, these forms were devoid of biological activity. In the late 1980s, bioactive GLP-1 peptides were purified from gut extracts and were identified to be GLP-1(7–37) and GLP-1(7–36)-amide. In the current literature, the unqualified designation of GLP-1 corresponds to the truncated peptides.
• Biological Functions: Glucagon-like peptide-1 (GLP-1) is an incretin, a natural peptide hormone secreted in response to food intake. Incretins have multiple physiological effects to lower blood sugar, including the stimulation of insulin release and the inhibition of glucagon release following meals.
• Clinical Use: GLP-1 enhances glucose-stimulated insulin release. GLP-1 agonists are resistant to degradation by DPP-4; thus these agonists are used clinically for the treatment of diabetes. DPP-4 inhibitors are also acceptable for use in diabetes patients because GLP-1 is rapidly deactivated by DPP-4.